US2007207962A1PendingUtilityA1

Intravenous blood-replacement solutions

Assignee: COLEMAN LEWISPriority: Mar 15, 2005Filed: Mar 26, 2007Published: Sep 6, 2007
Est. expiryMar 15, 2025(expired)· nominal 20-yr term from priority
Inventors:Lewis Coleman
A61K 31/36A61K 31/37
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the hypothesis that coagulation Factors VII and VIII are respectively local and systemic stress agents that regulate thrombin activity and synergize each other's effects. Stress Theory may explain the etiologies of several hitherto mysterious disease syndromes, and the stress mechanism and may play a more pervasive role in disease than is generally appreciated. The theory offers fresh avenues for research and clinical strategy.

Claims

exact text as granted — not AI-modified
1 . An intravenous blood-replacement solution for rapidly restoring normal blood viscosity, rheology, osmolarity, turbulence, mixing, and hemodynamic stability, comprising: 
 a. a fibrinogen;    b. an albumen;    c. a fibronectin; and    d. an electrolyte.    
   
   
       2 . The blood-replacement solution of  claim 1 , wherein the fibrinogen is selected from the group consisting of a human fibrinogen, an animal fibrinogen, and a combination of human and animal fibrinogen.  
   
   
       3 . The blood-replacement solution of  claim 1 , wherein the electrolyte comprises an element selected from the group consisting of a sodium, a magnesium, and a potassium.  
   
   
       4 . The blood-replacement solution of  claim 1 , wherein the electrolyte comprises a trace element found in normal blood.

Join the waitlist — get patent alerts

Track US2007207962A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.